Targeting the HIV trans-activation responsive region--approaches towards RNA-binding drugs.
about
Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptidesCell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cellsTwo-dimensional combinatorial screening identifies specific 6'-acylated kanamycin A- and 6'-acylated neamine-RNA hairpin interactions.Hoechst 33258 selectively inhibits group I intron self-splicing by affecting RNA folding.Two-dimensional combinatorial screening and the RNA Privileged Space Predictor program efficiently identify aminoglycoside-RNA hairpin loop interactionsUsing an emissive uridine analogue for assembling fluorescent HIV-1 TAR constructs.Dynamics-based amplification of RNA function and its characterization by using NMR spectroscopy.6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors.Use of RNA in drug design.Probing Na(+)-induced changes in the HIV-1 TAR conformational dynamics using NMR residual dipolar couplings: new insights into the role of counterions and electrostatic interactions in adaptive recognition.Evidence that electrostatic interactions dictate the ligand-induced arrest of RNA global flexibility.New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model.2,4-Diamino-6,7-dimethylpteridine as a fluorescent ligand for binding and sensing an orphan cytosine in RNA duplexes.
P2860
Q24793327-573EE553-3A06-4928-ADEC-0EF3BD5EC52BQ24814987-19F9389F-7FCB-4CC0-BC33-FB97747B57F7Q30851023-D3BC913B-776B-49F3-89A5-015D3446AD0CQ33208798-BC73327F-7F7A-4768-ACA6-F4F202F67CC3Q33499621-78CFF19E-FCCE-4F3F-85E0-E3EC9DC15741Q36014450-D4F3A8E6-5513-4290-B383-94B3011BF295Q36247149-930DF38B-6AA5-429F-B46E-6FF072C009E1Q37855902-6218B057-8F3C-4169-B3EB-A6DCB59C940CQ38089160-5DAE594E-053C-42A0-B288-F3FFBC70E96CQ42557759-1F64C40F-91D7-4614-A07E-9159C347F06CQ43117023-E438D4DD-7E73-488B-9356-6C4B95FAE5E1Q43814702-A4923621-2C5B-464B-8F8B-DA4B296431E7Q46115169-871CED58-B669-408C-A597-2AFD0C0668BF
P2860
Targeting the HIV trans-activation responsive region--approaches towards RNA-binding drugs.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Targeting the HIV trans-activa ...... hes towards RNA-binding drugs.
@ast
Targeting the HIV trans-activa ...... hes towards RNA-binding drugs.
@en
type
label
Targeting the HIV trans-activa ...... hes towards RNA-binding drugs.
@ast
Targeting the HIV trans-activa ...... hes towards RNA-binding drugs.
@en
prefLabel
Targeting the HIV trans-activa ...... hes towards RNA-binding drugs.
@ast
Targeting the HIV trans-activa ...... hes towards RNA-binding drugs.
@en
P2093
P2860
P356
P1433
P1476
Targeting the HIV trans-activa ...... hes towards RNA-binding drugs.
@en
P2093
Andreas Krebs
Michael W Göbel
Oliver Boden
Verena Ludwig
P2860
P304
P356
10.1002/CBIC.200300652
P577
2003-10-01T00:00:00Z